HITRI plus
Heavy Ion Therapy Research Integration

WP4 - NA3 - Innovation, technology transfer, industry relation

SANDRA MUHR, MANUELA CIRILLI (CERN)
CECILIA VOENA (INFN)
MARTINA BAUER (GSI)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

WP4:

devise and implement
a ROADMAP for
the INDUSTRIALISATION
of the HITRIplus
TECHNOLOGIES

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Three main tasks to achieve objectives

Task 4.1: Technology overview/assessment (CERN, GSI, INFN)

Task 4.2: Technology promotion (GSI, CERN, INFN)

Task 4.3: Technology matching (INFN, CERN, GSI)



HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Deliverables and Milestones

Deliverable Number[14]	Deliverable Title	Lead beneficiary	Type[15]	Dissemination level[16]	Due Date (in months)[17]
D4.1	HITRIplus technologies and dissemination plan	4 - CERN	Report	Confidential, only for members of the consortium (including the Commission Services)	28
D4.2	Value propositions	7 - GSI	Report	Public	28
D4.3	Technology matching event	9 - INFN	Report	Public	36

January 2024 ✓ Done

September 2024 ✓ In Progress

Milestone number[18]	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS4	First meeting of the Technology Overview committee	4 - CERN	8	Meeting of the Technology Overview committee, dedicated to the definition of the workplan.

November 2021 ✓ Done

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

D4.1: HITRIplus Technologies and dissemination plan

Deadline: January 2024

- Identifies technologies from WP7-12 and presents them as commercial opportunities
- Showcases project benefits to European Industry
  - Heavy ion therapy as a business case
  - Benefits beyond hadrontherapy
- Identifies valuable opportunities for partnerships and co-development
  - Within the consortium
  - With strategically selected companies

Ref. H2020-INFRAIA-2020-1- RIA GA - 101008548

Horizon 2020 - INFRAIA-2020-1

HITRI*plus*

Heavy Ion Therapy Research Integration

Project: 101008548– HITRI*plus*

Heavy Ion Therapy Research Integration *plus*

https://www.hitriplus.eu

Deliverable 4.1 HITRIplus technologies and dissemination plan

Date:	16/01/2024
Due Date	31/01/2024
Type:	Report
Dissemination Level:	Confidential
Work Package:	WP4
Lead Beneficiary:	CERN
Author(s):	S.Muhr
Contributing Beneficiaries:	GSI, INFN

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

HITRI*plus*
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

D4.2: Value Propostions - Targeted at companies

Deadline:
January 2023

HITRIplus Technology in the Report

- Description
- Challenge
- Solution
- Value
- Dissemination Route
- IP Protection
- Companies of Interest
- Action Plan
- Publications and Results

PowerPoint Versions

Brochure Versions



Value propositions for every technical WP:

- Available for presentations from the coordinator/technical WPs
- Available for display on TV screens at conferences

One brochure with 7 appendixes:

- Available for hand-out at conferences
- Available on project website
- Available for stream-out on social-media

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

D4.3: Technology Matching Event

Deadline:
September 2024

Marco Durante, PhD

- PTCOG (Particle Therapy Co-Operative Group) Chairman
- HITRIplus WP6 Leader

The HITRI booth

Participants: IBA, Leo Cancer Care, LinearBeam, Varian, Elekta, RaySearch Laboratories

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Results so far

- 12 HITRIplus Technologies Identified
- 3 Companies have signed the Memorandum of Understanding with the coordinator
- 19 Companies have expressed industrial interest
- 7 Value Propositions and one brochure for WP7-12 technologies have been produced targeting companies

Ongoing activities

- Communication and awareness of the HITRIplus technologies targeting companies on website and social media
- Active outreach to companies at conferences (PTCOG, and possibly ESTRO)
- Advising on usage of Technology Transfer Tools (e.g Legal Framework)

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Contact WP4 (wp4@hitriplus.eu)

Reach out to us:

- If you want the Value Propositions for the identified HITRIplus technologies to present or communicate about the project
- If you want us to contact a company at PTCOG Singapore about a HITRIplus technology
- If you want us to communicate about any technical WP developments to industry
- If you need advice on IP protection or dissemination strategies

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Happy to answer your questions

HITRI
Heavy Ion Therapy Research Integration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548